Advanced search
Publication Cover
Acta Cardiologica Volume 78, 2023 - Issue 5
Submit an article Journal homepage
132
Views
3
CrossRef citations to date
0
Altmetric
Original Scientific Papers

Value of repeated measurements of lipoprotein (a) to assess cardiovascular risk: a retrospective study

Axelle Deconincka Department of Cardiology, Erasme University Hospital, Brussels, BelgiumCorrespondence[email protected]
,
Sofia Morraa Department of Cardiology, Erasme University Hospital, Brussels, Belgium
,
Nina Glasséeb European Organisation for Research and Treatment of Cancer, Brussels, Belgium
&
Philippe van de Bornea Department of Cardiology, Erasme University Hospital, Brussels, Belgium
Pages 536-542 | Received 03 Aug 2021, Accepted 13 Jan 2022, Published online: 10 Feb 2022

References

  • Saeed A, Kinoush S, Virani SS. Lipoprotein (a): recent updates on a unique lipoprotein. Curr Atheroscler Rep. 2021;23(8):41.
  • Cegla J, France M, Marcovina SM, et al. Lp(a): when and how to measure it. Ann Clin Biochem. 2021;58(1):16–21.
  • Jawi MM, Frohlich J, Chan SY. Lipoprotein(a) the insurgent: a new insight into the structure, function, metabolism, pathogenicity, and medications affecting lipoprotein(a) molecule. J Lipids. 2020;2020:1–26.
  • Handhle A, Viljoen A, Wierzbicki AS. Elevated lipoprotein (a): background, current insights and future potential therapies. Vasc Health Risk Manag. 2021;17:527–542.
  • Pearson K, Rodriguez F. Lipoprotein (a) and cardiovascular disease prevention across diverse populations. Cardiol Ther. 2020;9(2):275–292.
  • Korneva VA, Kuznetsova TY, Julius U. Modern approaches to lower lipoprotein(a) concentrations and consequences for cardiovascular diseases. Biomedicines. 2021;9(9):1271.
  • Wyness SP, Genzen JR. Performance evaluation of five lipoprotein (a) immunoassays on the roche cobas c501 chemistry analyzer. Pract Lab Med. 2021;25:e00218.
  • ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart J. 2020; 41:111–188.
  • Tsimikas S. A test in context: lipoprotein (a) diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69(6):692–711.
  • Tsimikas S, Fazio S, Ferdinand KC, et al. NHLBI working group recommendations to reduce lipoprotein (a)-mediated risk of cardiovascular disease and aortic stenosis. J Am Coll Cardiol. 2018;71(2):177–192.
  • Marcovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application. J Lipid Res. 2016;57(4):526–537.
  • Enkhmaa B, Petersen KS, Kris-Etherton PM, et al. Diet and Lp (a): does dietary change modify residual cardiovascular risk conferred by Lp (a)? Nutrients. 2020;12(7):2024.
  • Burgess S, Ference BA, Staley JR, et al. European Prospective Investigation into Cancer and Nutrition Cardiovascular Disease (EPIC-CVD) consortium. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis. JAMA Cardiol. 2018;3(7):619–627.
  • Liu T, Yoon WS, Lee SR. Recent updates of lipoprotein(a) and cardiovascular disease. Chonnam Med J. 2021;57(1):36–43.
  • Raal FJ, Giugliano RP, Sabatine MS, et al. Reduction in lipoprotein (a) with PCSK9 monoclonal antibody evolocumab (AMG 145) a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol. 2014;63(13):1278–1288.
  • Shapiro MD, Minnier J, Tavori H, et al. Relationship between low‐density lipoprotein cholesterol and lipoprotein (a) lowering in response to PCSK9 inhibition with evolocumab. J Am Heart Assoc. 2019;8(4):e010932.
  • Shah NP, Pajidipati NJ, McGarrah RW, et al. Lipoprotein (a): an update on a marker of residual risk and associated clinical manifestations. Am J Cardiol. 2020;126:94–102.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Novo Nordisk – Driving change to defeat serious chronic diseases.
Novartis. Your partner in Heart Failure & Atherosclerosis >>

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.